Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37


Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.

Toplak H, Ludvik B, Lechleitner M, Dieplinger H, Föger B, Paulweber B, Weber T, Watschinger B, Horn S, Wascher TC, Drexel H, Brodmann M, Pilger E, Rosenkranz A, Pohanka E, Oberbauer R, Traindl O, Roithinger FX, Metzler B, Haring HP, Kiechl S.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S216-28. doi: 10.1007/s00508-016-0993-x.


Successful Direct Adsorption of Lipoproteins (DALI) Apheresis During Pregnancy in an Omani Woman with Homozygous Familial Hypercholesterolemia.

Al-Dughaishi T, Al-Waili K, Banerjee Y, Sheik S, Al-Sabti H, Al-Zakwani I, Al-Mukhaini S, Al Wahaibi K, Al-Hinai AT, Al-Rasadi K.

Open Cardiovasc Med J. 2015 Dec 29;9:114-7. doi: 10.2174/1874192401509010114.


Improved Hepatocyte Engraftment After Portal Vein Occlusion in LDL Receptor-Deficient WHHL Rabbits and Lentiviral-Mediated Phenotypic Correction In Vitro.

Goulinet-Mainot S, Tranchart H, Groyer-Picard MT, Lainas P, Saloum Diop P, Holopherne D, Gonin P, Benihoud K, Ba N, Gauthier O, Franco D, Guettier C, Pariente D, Weber A, Dagher I, Huy Nguyen T.

Cell Med. 2012 May 8;4(2):85-98. doi: 10.3727/215517912X647136.


Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Hegele RA, Gidding SS, Ginsberg HN, McPherson R, Raal FJ, Rader DJ, Robinson JG, Welty FK.

Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2269-80. doi: 10.1161/ATVBAHA.115.306442. Review.


Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.

Ito MK, Watts GF.

Drugs. 2015 Oct;75(15):1715-24. doi: 10.1007/s40265-015-0466-y. Review.


Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel.

Al-Ashwal A, Alnouri F, Sabbour H, Al-Mahfouz A, Al-Sayed N, Razzaghy-Azar M, Al-Allaf F, Al-Waili K, Banerjee Y, Genest J, Santos RD, Al-Rasadi K.

Curr Vasc Pharmacol. 2015;13(6):759-70.


Familial hypercholesterolemia.

Bouhairie VE, Goldberg AC.

Cardiol Clin. 2015 May;33(2):169-79. doi: 10.1016/j.ccl.2015.01.001. Review.


The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M; Phase 3 HoFH Lomitapide Study Investigators..

Atherosclerosis. 2015 Jun;240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014.


Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management.

Najam O, Ray KK.

Cardiol Ther. 2015 Jun;4(1):25-38. doi: 10.1007/s40119-015-0037-z.


Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels.

Xie P, Zhu H, Jia L, Ma Y, Tang W, Wang Y, Xue B, Shi H, Yu L.

Atherosclerosis. 2014 Dec;237(2):609-17. doi: 10.1016/j.atherosclerosis.2014.09.036.


Familial hypercholesterolemia: developments in diagnosis and treatment.

Klose G, Laufs U, März W, Windler E.

Dtsch Arztebl Int. 2014 Aug 4;111(31-32):523-9. doi: 10.3238/arztebl.2014.0523. Review.


Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia..

Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274.


Familial hypercholesterolemia: A review.

Varghese MJ.

Ann Pediatr Cardiol. 2014 May;7(2):107-17. doi: 10.4103/0974-2069.132478. Review.


Dyslipidemic drugs in metabolic syndrome.

Siddiqi SS, Misbahuddin, Ahmad F, Rahman SZ, Khan AU.

Indian J Endocrinol Metab. 2013 May;17(3):472-9. doi: 10.4103/2230-8210.111644.


Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study investigators..

Lancet. 2013 Jan 5;381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0.


Low-density lipoprotein apheresis: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2007;7(5):1-101.


Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Thongtang N, Lin J, Schaefer EJ, Lowe RS, Tomassini JE, Shah AK, Tershakovec AM.

Atherosclerosis. 2012 Dec;225(2):388-96. doi: 10.1016/j.atherosclerosis.2012.09.001.


Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

Luvai A, Mbagaya W, Hall AS, Barth JH.

Clin Med Insights Cardiol. 2012;6:17-33. doi: 10.4137/CMC.S4324.


Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ.

J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847.

Supplemental Content

Support Center